China-Japan Friendship Hospital

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

Retrieved on: 
Tuesday, December 20, 2022
Hospital, Severe acute respiratory syndrome coronavirus 2, Ritonavir, Neuropsychiatric Disease and Treatment, SIMM, Chinese Academy of Sciences, Patient, National Medical Products Administration, Trial of the century, Clinical trial, Central nervous system, Phase, Simcere Pharmaceutical, Drug discovery, Biotechnology, Capacity building, Fatality, Health, Degenerative disease, III, China-Japan Friendship Hospital, COVID-19, Medicine, Technology transfer, Safety, Post-exposure prophylaxis, National Center for Advancing Translational Sciences, Peking Union Medical College, Infection, Wuhan Institute of Virology, WIV, Cancer, NDA, Fear, FPI, Viral load, New Drug Application, Wuhan Jinyintan Hospital, Research, CAS, Pharmaceutical industry, Materia medica, Study, Virology

Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.

Key Points: 
  • Simcere will accelerate the analysis of clinical study results and actively prepare for New Drug Application (NDA), while speeding up the expansion of production capacity to meet urgent clinical needs.
  • This is to fulfill the Group's corporate mission of "providing today's patients with medicines of the future".
  • The Study has established a total of 43 clinical research centers in 20 provinces, municipalities and autonomous regions in China.
  • XIANNUOXIN is a combination packaged drug of a small molecule anti- SARS-CoV-2 drug candidate and Ritonavir, this candidate is targeted 3CL protease which is essential for SARS-CoV-2 viral replication.

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Retrieved on: 
Tuesday, June 7, 2022
DREAM, Woman, National Medical Products Administration, GK, Company, FPG, GKA, Observation, DAWN, Research, Jak Airport, ADA, CEO, Education, Disease, World Diabetes Day, Type 2 diabetes, Insulin resistance, Patient, Glycated hemoglobin, Insulin, Metformin, Trial of the century, Chinese, Glucokinase, Type 2, Association, American Diabetes Association, Department, Public health, Hospital, NDA, Blood, Homeostasis, Drug development, Chinese University of Hong Kong, Attention, Glucose clamp technique, China-Japan Friendship Hospital, WIN, SEED, Pharmaceutical industry, Epidemiology, Diabetes, T2D

A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).

Key Points: 
  • A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).
  • Another clinical study called SENSITIZE also provided clinical scientific data of dorzagliatin in improving insulin secretion and glucose sensitivity.
  • The study results, using glucose clamp technique, showed that dorzagliatin can significantly improve second phase insulin secretion and glucose sensitivity in GCK-MODY patients and can significantly improve basal insulin secretion rates in patients with recent onset T2D.
  • Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China.

ELIAS Animal Health Announces Addition of Sales, Marketing & Business Development Leader and Expansion of Scientific Advisory Board

Retrieved on: 
Tuesday, November 23, 2021
CFR, Animal, CEO, Animal Health, Texas A&M University, Canine cancer detection, Elanco, Georgia Board of Regents, Marketing, Cancer, Clinical trial, University, Oncology, DVM, China-Japan Friendship Hospital, Medicine, Veterinarian, Dog, Hospital, Organization, Journal of Veterinary Internal Medicine, American College, Board, DRS, Immunotherapy, Veterinary medicine, Cat, Business development

"Caroline's experience in life sciences and proven ability to propel organizations forward will be critical as ELIAS looks to expand its immunotherapy pipeline," said Tammie Wahaus, CEO of ELIAS Animal Health.

Key Points: 
  • "Caroline's experience in life sciences and proven ability to propel organizations forward will be critical as ELIAS looks to expand its immunotherapy pipeline," said Tammie Wahaus, CEO of ELIAS Animal Health.
  • She has held positions at CEVA Animal Health, then known as Sanofi Animal Health, and Bayer Animal Health.
  • Her responsibilities have included mainly global roles in the commercial functions of Sales, Marketing and Business Development, including the licensing of technologies in and out.
  • Based inOlathe, Kan., ELIAS Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapies for the treatment of canine cancers.